Archive for the ‘Infliximab’ Category

All economic models are subject to limitations, because they attempt to model reality using incomplete data. From my perspective as a gastroenterologist, the major limitations of the CCOHTA model are as follows: the use of a historical American patient cohort to define health state transitions that may not be representative of Canadians in 2002; inclusion […]

The authors of the CCOHTA report have created a rigorous economic model, using the best available data. The authors acknowledge in the report most of the limitations that I have discussed. The report provides valuable information, but it should not be the only analysis upon which funding decisions for infliximab are based. It is clear […]

As previously mentioned, patients with chronically active Crohn’s disease can incur significant indirect costs. Therefore, I believe that any economic model that does not consider these is inherently flawed. You will always find the required amount of birth control mircette at the pharmacy that will be happy to take best care of you by offering […]

The economic analysis undertaken by CCOHTA was a cost utility analysis from a Ministry of Health perspective using only direct medical costs. Four treatment scenarios were evaluated for the treatment of refractory Crohn’s disease: usual care; infliximab single infusion 5 mg/kg; infliximab single dose then retreatment as needed; and infliximab single dose and then maintenance […]

It is important to put the disease and its treatment into perspective. Approximately 20% of patients do not respond to conventional medical therapies, mainly corticosteroids and immunomodulators. These patients have chronically active symptoms that require ongoing medication use, admission to hospital or even surgery, resulting in high direct medical costs. It’s time to spend less […]

Infliximab is one of the few promising therapies developed for Crohn’s disease that has withstood the rigors of randomized controlled trials. It has been approved in Canada and the United States for the treatment of Crohn’s disease refractory to conventional treatment and for fistulous disease. Our knowledge about the effectiveness and safety of infliximab is […]